Bristol Myers Squibb To Present New Clinical And HEOR Data in Schizophrenia At Psych Congress 2024

Bristol Myers Squibb to present new clinical and HEOR data from its neuropsychiatry portfolio evaluating Cobenfy in schizophrenia at Psych Congress 2024

Overview

Bristol Myers Squibb announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating Cobenfy (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 – November 2 in Boston, Massachusetts.

Statement from Bristol Myers Squibb

• Building on momentum from the recent US Food and Drug Administration’s approval of Cobenfy for the treatment of schizophrenia in adults, we’re pleased to be sharing additional data at Psych Congress from the EMERGENT clinical trial programme that further highlights the differentiated clinical profile of Cobenfy, including efficacy, safety, and patient reported outcomes of adults with schizophrenia who participated in our long-term clinical trials,” said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, immunology, cardiovascular and neuroscience, Bristol Myers Squibb. 
• As we continue to strengthen our neuropsychiatry portfolio, we remain committed to developing and delivering differentiated options for patients.

Data from poster presentations

Research to be presented at the meeting continues to demonstrate Cobenfy as a differentiated treatment option for adults living with schizophrenia. Notable data poster presentations include:

• Clinical: Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: 

Results from the 52-Week, open-label EMERGENT-4 Trial; Long-term safety, tolerability, and efficacy of xanomeline and trospium chloride in people with schizophrenia: 
results from the 52-week, open-label emergent-5 trial; patient satisfaction with xanomeline and trospium chloride treatment for schizophrenia: a qualitative interview-based study; changes in quality of life for schizophrenia outpatients receiving the muscarinic agonist xanomeline and trospium: Findings of a qualitative interview-based study.

• HEOR: Negative symptoms and cognitive impairment in US patients with schizophrenia: a real-world descriptive study using the NeuroBlu database; Comparative efficacy, safety, and tolerability of xanomeline and trospium chloride versus eight atypical antipsychotics for the acute treatment of adults with schizophrenia – A network meta-analysis; current estimates of the incidence and prevalence of schizophrenia in the US.

About the Disorder: Schizophrenia

• Schizophrenia is a persistent and often disabling mental illness impacting how a person thinks, feels and behaves. 
• There are three symptom domains of schizophrenia, which include positive symptoms (e.g., hallucinations, delusions, disordered thinking and speech), negative symptoms (e.g., lack of motivation, lack of emotional expression/flat affect, social withdrawal) and cognitive dysfunction (e.g., impaired attention, deficits in memory, concentration and decision-making). 
• The symptoms of schizophrenia can affect all areas of people’s lives, making it difficult to maintain employment, live independently and manage relationships. 
• Schizophrenia affects nearly 24 million people worldwide, including 2.8 million people in the United States, and is one of the top 15 leading causes of disability worldwide.

About Cobenfy

• Cobenfy (xanomeline and trospium chloride), formerly KarXT, is an oral medication for the treatment of schizophrenia in adults. 
• Cobenfy combines xanomeline, a dual M 1 - and M 4 -preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that does not appreciably cross the blood-brain barrier, primarily confining its effects to peripheral tissues. 
• While the exact mechanism of action of Cobenfy is unknown, its efficacy is thought to be due to the agonist activity of xanomeline at M 1 and M 4 muscarinic acetylcholine receptors in the central nervous system.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!